Adherence and persistence: Impact on outcomes and health care resources

[en] Non-adherence to and poor persistence with antiresorptive medication are significant problems in preventing adverse consequences of osteoporosis. Adherence rates for oral bisphosphonate therapy drop off dramatically during the first year of treatment and continue to decline thereafter. Inadequate adherence is associated with smaller decreases in rate of bone turnover, smaller bone mineral density (BMD) gains, and greater risk of fracture. Measures to improve patient adherence include improved physician/patient communication, close monitoring, and early intervention in declining adherence. Another approach is strengthening of patient commitment through reinforcement of the connection between treatment response and quality of life benefits. Use of biochemical markers of response or BMD measurements to illustrate response to patients may be useful in this regard. Simplification of treatment regimens would also be of considerable value in improving adherence and persistence. (c) 2005 Elsevier Inc. All rights reserved.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Adherence and persistence: Impact on outcomes and health care resources

Publication date :

February 2006

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier Science Inc, New York, United States - New York

Volume :

Issue :

2 Suppl 2

Pages :

S18-21

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 August 2009

Statistics

Number of views

51 (2 by ULiège)

Number of downloads

3 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

J.C. Sung, M.B. Nichol, F. Venturini, K.L. Bailey, J.S. McCombs, and M. Cody Factors affecting patient compliance with antihyperlipidemic medications in an HMO population Am. J. Manag. Care 4 1998 1421 1430
J.A. Rizzo, and W.R. Simons Variations in compliance among hypertensive patients by drug class: implications for health care costs Clin. Ther. 19 1997 1446 1457
A. Giuffrida, and D.J. Torgerson Should we pay the patient? Review of financial incentives to enhance patient compliance BMJ 315 1997 703 707
R.A. Yood, S. Emani, J.I. Reed, B.E. Lewis, M. Charpentier, and E. Lydick Compliance with pharmacologic therapy for osteoporosis Osteoporos. Int. 14 2003 965 968
J.S. McCombs, P. Thiebaud, C. McLaughlin-Miley, and J. Shi Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 2004 271 287
N.H. Miller Compliance with treatment regimens in chronic asymptomatic diseases Am. J. Med. 102 1997 43 49
W.S. Bond, and D.A. Hussar Detection methods and strategies for improving medication compliance Am. J. Hosp. Pharm. 48 1991 1978 1988
R. Eastell, P. Gamero, B. Vrijens, L. van de Langerjit, H.A.P. Pols, and J.D. Ringe Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study Calcif. Tissue Int. 72 2003 297 408
J. Finigan, P.R. Bainbridge, and R. Eastell Adherence to osteoporosis therapies Osteoporos. Int. 12 2001 S48 S49 [Abstract P110]
J.J. Caro, K.J. Ishak, K.F. Huybrechts, G. Raggio, and C. Naujoks The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos. Int. 15 2004 1003 1008
General Practitioners Research Database, UK. Available at: http://www.gprd.com/home/. Accessed May 4, 2005.
C. Lombas, C. Hakim, and J.R. Zanchetta Compliance with alendronate treatment in an osteoporosis clinic J. Bone Miner. Res. 16 Suppl 1 2001 S529 [Abstract M406]
A.N. Tosteson, M.R. Grove, C.S. Hammond, M.M. Moncur, G.T. Ray, and G.M. Hebert Early discontinuation of treatment for osteoporosis Am. J. Med. 115 2003 209 216
F. Bandeira, M. Kayath, J. Marqus-Neto, S. Ragi, J. Danovski, and S. Radominski Patients' clinical features and compliance associated with raloxifene or alendronate after a 6-month observational Brazilian study J. Bone Miner. Res. 18 Suppl 2 2003 S379 [Abstract M352]
R.J. Sebaldt, L.G. Shane, B.Z. Pham, R.J. Cook, L. Thabane, and A. Petrie Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis J. Bone Miner. Res. 19 Suppl 1 2004 S445 [Abstract M423]
L.B. Tankó, U. Mouritzen, H.J. Lehmann, L. Warming, A. Moelgaard, and S. Christgau Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens Bone 32 2003 687 693
E. Bronder, and A. Klimpel Unused drugs returned to the pharmacy-New data Int. J. Clin. Pharmacol. Ther. 39 2001 480 483
S.D. Sullivan, D.H. Kreling, and T.K. Hazlet Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate J. Res. Pharm. Econ. 2 1990 19 33
N. Col, J.E. Fanale, and P. Kronholm The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly Arch. Intern. Med. 150 1990 841 845
J.S. Berg, J. Dischler, D.J. Wagner, J.J. Raia, and N. Palmer-Shevlin Medication compliance: a healthcare problem Ann. Pharmacother. 27 1993 S5 S24 [Suppl]
E.W. Seely, A. Ravnikar, and B.L. McClung Patient-provider decisions about long-term therapy Am. J. Manag. Care 4 2 Suppl 1998
S.R. Eastaugh, and M.E. Hatcher Improving compliance among hypertensives: a triage criterion with cost-benefit implications Med. Care 20 1982 1001 1017
J.A. Clowes, N.F. Peel, and R. Eastell The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J. Clin. Endocrinol. Metab. 89 2004 1117 1123
A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin. Ther. 23 2001 1296 1310
B. Hamilton, K. McCoy, and H. Taggart Tolerability and compliance with risedronate in clinical practice Osteoporos. Int. 14 2003 259 262